Best Cash-Pay GLP-1 for Seniors on Medicare: 2026 Prices & Paths

If this sounds like you, start here

The four-path decision matrix every Medicare senior needs

Most pages on this topic answer one piece of the puzzle. Either they explain Medicare’s weight-loss exclusion and stop there, or they hand you a list of telehealth providers without telling you which ones accept Medicare patients. There are four real paths in 2026. Find the one that matches you.

Sources verified April 25, 2026: CMS Medicare GLP-1 Bridge FAQ (cms.gov, updated April 6, 2026 to add Foundayo and clarify Zepbound KwikPen-only inclusion); CMS April 21, 2026 BALANCE Model decision and Bridge extension; NovoCare Wegovy savings page; LillyDirect Foundayo Self-Pay Journey Program terms; Ro Weight Loss Pricing and Insurance pages; Sesame Care GLP-1 program pages.

What is the best cash-pay GLP-1 for seniors on Medicare?

The best cash-pay GLP-1 for seniors on Medicare depends on whether you can use the Medicare GLP-1 Bridge or a Part D-covered diagnosis first; if neither applies, FDA-approved cash-pay starts at $149/month for Wegovy pill or Foundayo (lowest dose), with Ro Body as our primary telehealth pick because its published policy explicitly lets Medicare beneficiaries pay out of pocket for cash-pay medication. The rest of this guide explains why and lays out every path with real numbers and honest tradeoffs.

For most seniors, the decision sequence is this:

1. 1
   Check the Bridge first. If you meet CMS's eligibility criteria, $50/month flat is cheaper than any cash-pay route.
2. 2
   Check Part D second. If you have type 2 diabetes, established cardiovascular disease, or moderate-to-severe sleep apnea, your Part D plan may already cover a GLP-1 for that indication.
3. 3
   Cash-pay third — and this is where Ro Body or Sesame Care come in. Ro for the broadest FDA-approved formulary and explicit Medicare cash-pay language. Sesame for lower membership fees and provider choice.

Can you pay cash for a GLP-1 if you have Medicare?

Yes, Medicare beneficiaries can pay cash for FDA-approved GLP-1s through manufacturer-direct programs (NovoCare Pharmacy, LillyDirect) and through certain telehealth platforms with Medicare-friendly cash-pay language (Ro Body), but cash-pay costs do not count toward your Medicare Part D deductible or your $2,100 out-of-pocket cap, and you cannot use the manufacturer’s $25/month savings card — federal law excludes Medicare beneficiaries from those copay assistance programs.

What does it leave you with?

• The Bridge program (when it launches July 1, 2026) — designed specifically to give Medicare patients a $50/month price.
• Part D coverage when your diagnosis qualifies (diabetes, CVD, OSA).
• Cash-pay outside any insurance — manufacturer-direct, telehealth, or compounded.

Does Medicare cover GLP-1 medications for weight loss in 2026?

Medicare Part D is statutorily prohibited from covering drugs prescribed solely for weight loss, but two pathways now exist: the Medicare GLP-1 Bridge (a CMS demonstration providing $50/month copay for eligible Foundayo, Wegovy, and Zepbound KwikPen prescriptions from July 1, 2026 through December 31, 2027), and Part D coverage for FDA-approved indications other than weight loss (Ozempic and Mounjaro for type 2 diabetes; Wegovy for cardiovascular risk reduction; Zepbound for moderate-to-severe sleep apnea).

Many seniors qualify for one of these pathways without realizing it.

Path 1: The Medicare GLP-1 Bridge ($50/month, starting July 1, 2026)

The Medicare GLP-1 Bridge is a Centers for Medicare & Medicaid Services (CMS) demonstration program providing eligible Part D beneficiaries with $50/month copay access to certain GLP-1 medications used for weight loss. It exists because Medicare is statutorily prohibited from covering weight-loss drugs, and the federal government negotiated a workaround with manufacturers. If you qualify, this is the cheapest legitimate path.

What’s covered

Per CMS guidance updated April 6, 2026, the Bridge covers three medications when prescribed to reduce excess body weight and maintain weight reduction:

• ✓Foundayo® (orforglipron) — all formulations
• ✓Wegovy® — injection and tablets, all formulations
• ✓Zepbound® — KwikPen® formulation only — single-dose vials and single-dose pens are NOT covered

Who qualifies — the exact CMS criteria

A provider must submit a prior authorization attesting you meet all of the following:

If you started a GLP-1 before July 1, 2026 and your BMI has dropped, your prescriber can attest you met the BMI criterion at initiation of therapy — you stay eligible.

Plan-type eligibility

The Bridge is nationwide. You must be enrolled in a standalone Part D plan (PDP) or a Medicare Advantage coordinated care plan with Part D coverage (HMO, HMOPOS, Local/Regional PPO with prescription drug coverage). Special Needs Plans, employer/union group waiver plans, and the Limited Income Newly Eligible Transition program are eligible. Dually-eligible Medicare/Medicaid beneficiaries enrolled in eligible Part D plan types are eligible. Private fee-for-service plans without Part D and Medicare supplement (Medigap) policies alone are not eligible. CMS has confirmed that Part D sponsors do not have to opt in to the Bridge for eligible beneficiaries to access these drugs beginning July 1, 2026.

How it actually works

Your prescriber submits the prior authorization to a single CMS central processor — administered by Humana through the Limited Income Newly Eligible Transition (LI NET) infrastructure — not to your Part D plan. Once approved, you fill at any pharmacy. You pay $50 at the counter. CMS reimburses the pharmacy at wholesale acquisition cost. Manufacturers accepted $245/month as the negotiated net price for eligible Bridge claims.

The two catches

What changed on April 21, 2026

CMS announced that the BALANCE Model — which was supposed to fold Bridge benefits into permanent Part D coverage starting January 2027 — will not launch in Medicare Part D in 2027 as planned. Health insurers refused to participate at the rates CMS proposed. To preserve access, CMS extended the Bridge program itself through December 31, 2027. The Bridge does not “end” on December 31, 2026 the way some older articles describe. Eligible beneficiaries are covered through the end of 2027.

What to do between now and July 1, 2026

1. 1Confirm you're on a standalone Part D plan or MA-PD for 2026.
2. 2Get your BMI documented at your next physical. Pull historical BMI records if you've lost weight on a previous program.
3. 3If you have one of the qualifying comorbidities, get the diagnosis formally on your chart with the appropriate ICD-10 code.
4. 4If you currently use Zepbound vials, talk to your prescriber about switching to the KwikPen formulation before July 1.
5. 5Tell your prescriber you intend to use the Bridge. Ask them to be ready to submit the prior auth to the CMS central processor on July 1.
6. 6Watch for additional CMS operational guidance coming in Spring 2026.

Paths 2 and 3: The Part D “backdoor” — covered today, if you have the right diagnosis

Medicare Part D already covers GLP-1s for indications other than weight loss. If you have any of these on your chart, you don’t need to wait for July 1, you don’t need to pay cash, and your costs count toward the 2026 Part D $2,100 out-of-pocket cap. Many seniors qualify without realizing it.

How to navigate prior authorization

1. 1
   Confirm the indication is on your chart. If your CVD, OSA, or diabetes is "implied" rather than formally documented, the prior auth will fail. Get the formal diagnosis added at your next visit.
2. 2
   Have your prescriber submit the prior auth to your Part D plan with indication-specific documentation: BMI, comorbidity records, prior weight-loss attempts where the formulary requires it, and the diagnosis ICD-10 code.
3. 3
   If denied, appeal. Initial Part D denials are often reversed when the specific denial reason is addressed with additional clinical documentation. Your prescriber can write a letter of medical necessity. CMS preserves your full Part D appeal rights, including exception requests.

Path 4a: Manufacturer-direct cash-pay (the cheapest legitimate FDA-approved option)

If you can’t use the Bridge or a Part D backdoor, the cheapest cash-pay path to FDA-approved GLP-1s is buying directly from Novo Nordisk or Eli Lilly. Wegovy pill and Foundayo both start at $149/month for the lowest dose. Zepbound starts at $299/month for the 2.5 mg starter. Verified April 25, 2026.

Wegovy pill (semaglutide) — $149/month entry

Source: NovoCare Wegovy savings page, verified April 25, 2026.

Wegovy injection (semaglutide) — $349/month standard

Source: NovoCare Wegovy savings page, verified April 25, 2026.

Foundayo (orforglipron) — $149/month entry, FDA-approved April 1, 2026

Foundayo is a once-daily oral, non-peptide small-molecule GLP-1 receptor agonist — distinct from semaglutide and tirzepatide. FDA approved April 1, 2026. Available through LillyDirect April 6, 2026. Unlike Wegovy pill, Foundayo can be taken any time of day, with or without food or water restrictions.

Source: LillyDirect Foundayo coverage and savings page, verified April 25, 2026.

Zepbound (tirzepatide) — $299/month starter

Source: zepbound.lilly.com/savings, verified April 25, 2026.

How to actually buy directly from the manufacturer

1. 1Get a prescription from any U.S.-licensed prescriber — your PCP, your endocrinologist, or a telehealth platform.
2. 2Send it to NovoCare Pharmacy (Wegovy and Ozempic) or LillyDirect (Zepbound and Foundayo).
3. 3Pay cash at the listed price. Medication ships to your home, or you can pick up at a participating local pharmacy.

You don’t need a savings card to access these prices. The savings card is the commercial-insurance discount path that excludes Medicare. The cash-pay direct prices above are the published self-pay rates, with the NovoCare-specific Medicare conditions noted above.

Path 4b: Best telehealth cash-pay programs that accept Medicare patients

Two telehealth platforms are good fits for Medicare seniors paying cash for FDA-approved GLP-1s: Ro Body (whose published policy explicitly allows Medicare, Medicare supplement, and TRICARE users to join and pay out of pocket) and Sesame Care (which offers cash-pay GLP-1 access with provider choice and lower membership fees). Neither will coordinate insurance for government plans. Both let you pay cash for the medication while a clinician guides the program.

Pricing verified April 25, 2026 from ro.co/weight-loss/pricing and sesamecare.com.

Should you wait for the Bridge, or pay cash now?

If you’ll likely qualify for the Bridge and you can wait until July 1, 2026, waiting is worth it for most seniors. $50/month versus $149–$299/month for cash-pay is a difference of $100–$250 per month, or $1,200–$3,000 over a year. For most Medicare seniors on a fixed income, that’s not a small difference.

If you can’t wait — if your weight or comorbidities are urgent, or you’ve been off treatment and want to restart now — paying cash through Ro Body, Sesame Care, or NovoCare/LillyDirect for the months between now and July, then transitioning to the Bridge in July, is a legitimate strategy.

FDA-approved versus compounded GLP-1s: what Medicare seniors should choose first

For the senior population specifically, FDA-approved cash-pay options are the better first choice over compounded. Three reasons. The senior body has more comorbidities, more medications, and a higher-risk profile. FDA review for brand-name drugs gives you a layer of safety, efficacy, and quality data that compounded versions don’t have. Drug-interaction profiles are better documented for brand-name GLP-1s. And the price gap that used to make compounded compelling has narrowed — Wegovy pill and Foundayo at $149/month for the lowest dose are now within $20 of the cheapest compounded options.

Compliant language — for your protection

Compounded fallback options (only after FDA-approved cash-pay is ruled out)

If FDA-approved cash-pay is genuinely unaffordable, these compounded providers had the most visible pricing and visible compounded-status disclosures in our source check. Each is a fallback, not a first choice. Every option below is a compounded medication — not FDA-approved; not reviewed by FDA for safety, effectiveness, or quality.

Pricing verified April 25, 2026 from each provider’s pricing pages.

Which cash-pay GLP-1 route is cheapest over 12 months?

Across a full year, the Bridge program is the cheapest at $300 (partial 2026) or $600 (full year). FDA-approved cash-pay through manufacturer-direct or telehealth runs $1,788 to $5,188+ depending on medication, dose, and program fees. Compounded fallback runs $1,752 to $2,868. Real numbers, not estimates:

*Assumes 45-day refill rule met every month. Verified April 25, 2026. Annual estimates exclude taxes, shipping, and lab fees. Manufacturer prices are subject to change; some are tied to limited-time offers (Wegovy pill 4 mg promotional pricing through August 31, 2026; $199 intro Wegovy injection offer through June 30, 2026).

Are GLP-1s safe for adults over 65?

FDA labeling and clinical trial data include adults 65+, but data in adults 75+ are thinner, and dosing protocols for older adults should be calibrated for frailty risk, sarcopenia, kidney function, drug interactions, and dehydration risk. This is not an age cutoff — it’s a clinical assessment your prescriber should make with you, based on your overall health, your current medications, your kidney function, and your treatment goals.

Who is and isn’t a candidate

Generally less appropriate for:

• ✗Frailty, sarcopenia, or recent fall history
• ✗Personal or family history of medullary thyroid carcinoma or MEN 2 (boxed warning)
• ✗Prior or active pancreatitis
• ✗Severe gastroparesis or GI motility disorders
• ✗Severe gallbladder disease
• ✗Significant unintentional weight loss already occurring
• ✗Significant dementia or geriatric syndromes affecting medication management

This list paraphrases FDA prescribing information and reflects general geriatric medicine guidance. The decision for your specific situation is your prescriber’s.

Senior-relevant considerations to discuss with your prescriber

Side effects to watch for

The 12-point cash-pay GLP-1 verification checklist for Medicare seniors

Before you commit to any cash-pay GLP-1 provider, verify these 12 things in writing. Built specifically for the Medicare-senior decision context, where the wrong provider can cost real money or compromise safety.

If a provider can’t answer all 12 in writing, choose somewhere else.

What we actually verified for this guide

We checked CMS guidance, FDA published warnings and Drug Safety Communications, manufacturer pricing pages, and provider policy pages on April 25, 2026. Where a provider page is the source, we describe pricing as “provider-stated.” Where CMS or FDA is the source, we describe it as “verified from CMS/FDA.”

How we ranked these options

This is an editorial ranking, not a medical judgment that one medication or provider is clinically best for every senior. We don’t accept vendor compensation to determine ranking order. We do disclose where we earn affiliate commissions (Ro, Sesame, Eden, Yucca, SHED, MEDVi).

Real-user experience signals (not medical outcome proof)

Most provider testimonials are paid spokesperson quotes or anonymous reviews we can’t independently verify. Ro publicly notes that its featured members were paid for their testimonials, which is appropriate disclosure but means those quotes don’t independently validate process or outcomes. If you’ve used one of the providers on this page and want to share your experience for a future update, contact: [email protected].

Frequently asked questions

Putting it all together — your next step today

Most Medicare seniors reading this fall into one of three buckets. Pick yours and act this week.